Drugs / Requip PR
last change Mar 2012 re-read 3 minutes ago

Requip PR

Developed for
Parkinson disease
Investigated by
GlaxoSmithKline

Trials 1

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01536574 Sep 2010 → Mar 2012 Parkinson disease GlaxoSmithKline Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Requip PR ClinicalTrials.gov intervention name — accepted as the source's own label NCT01536574 ↗